ASH 2021 | Daratumumab in the treatment of high-risk MGUS and low-risk smoldering myeloma
Irene Ghobrial
• 11 Dec 2021
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses two ongoing Phase II clinical trials: one investigating the use of daratumumab in high-risk monoclonal gammopathy of undetermined significance (MGUS) and low-risk smoldering multiple myeloma (SMM), and the other investigating ixazomib, lenalidomide and dexamethasone in high-risk SMM. Dr Ghobrial explains the main aims of these trials, which is to investigate the safety and efficacy of daratumumab in low-risk SMM, as well as look for new methods to prevent patients with low-risk smoldering myeloma from entering the high-risk category. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
